ClinConnect ClinConnect Logo
Search / Trial NCT00000783

Heterosexual HIV Transmission Study (HATS)

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of July 05, 2025

Completed

Keywords

Sex Behavior Sexual Partners

ClinConnect Summary

In the United States, the number of AIDS cases attributed to heterosexual transmission, although still a small percentage of the total number of reported cases, is the most rapidly growing category. The rate at which HIV is transmitted between heterosexual couples and the factors that may impede or enhance heterosexual transmission are important to understanding and slowing the worldwide HIV epidemic.

This epidemiologic study is composed of three parts. PART A: In a prospective study, heterosexual couples who are discordant with respect to HIV infection will be evaluated at 6-month interva...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Risk Behavior:
  • PART B ONLY:
  • HIV-infected partner (primary partner) must have a known risk factor for HIV infection, such as
  • Bisexual male.
  • IV drug user.
  • Hemophiliac male.
  • Recipient of HIV-contaminated transfusion.
  • Participants must meet the following criteria:
  • Heterosexual couples in which at least one member is HIV-infected. Comparison group consists of heterosexual couples concordant that are both HIV infected.
  • Able to speak English or Spanish.
  • PART A secondary partners:
  • Risk factor for HIV infection other than heterosexual contact, such as
  • Evidence of any past or present parenteral drug use by self report, physical examination, or urine test.
  • History of homosexual activity (if male) within 5 years prior to study entry.
  • PART B secondary partners:
  • Risk factor for HIV infection other than sexual contact with the primary partner, such as
  • Evidence of any past or present parenteral drug use by self-report or by urine test.
  • History of homosexual activity (if male) at any time since 1978.
  • Sexual contact with another person with an HIV risk factor at any time since 1978, unless secondary partner is documented to be HIV uninfected subsequent to the last contact with such person.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Newark, New Jersey, United States

Patients applied

0 patients applied

Trial Officials

O'Brien

Study Chair

Cordell

Study Chair

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials